Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients

SIMPLE SUMMARY: Cetuximab is an antibody that blocks EGFR signaling and stimulates an immune response against cancer cells. For patients with advanced colorectal cancer, tumor sidedness and RAS mutation status are the primary factors used to select systemic therapy. Additional biomarkers are needed...

Descripción completa

Detalles Bibliográficos
Autores principales: Volz, Nico B., Hanna, Diana L., Stintzing, Sebastian, Zhang, Wu, Yang, Dongyun, Cao, Shu, Ning, Yan, Matsusaka, Satoshi, Sunakawa, Yu, Berger, Martin D., Cremolini, Chiara, Loupakis, Fotios, Falcone, Alfredo, Lenz, Heinz-Josef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601940/
https://www.ncbi.nlm.nih.gov/pubmed/33065994
http://dx.doi.org/10.3390/cancers12102947

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601940/
https://www.ncbi.nlm.nih.gov/pubmed/33065994
http://dx.doi.org/10.3390/cancers12102947

Ejemplares similares